1. Home
  2. |Insights
  3. |Lifecycle of a Deal – Handling the Competition and FDI Aspects of M&A Transactions

Lifecycle of a Deal – Handling the Competition and FDI Aspects of M&A Transactions

Webinar | 11.16.26, 12:30 PM CET - 2:00 PM CET

Address

Virtual

Register Here

Every deal has a lifecycle — and at each stage, competition law and foreign direct investment (FDI) rules have the potential to change the outcome. Knowing where the risks lie, and how to manage them, can make all the difference.
Join us for a practical session in which we will guide you through the full lifecycle of a deal from a competition and FDI perspective, and explore important questions such as:
  • What competition law considerations arise at the different stages of a transaction, and what risks should you watch out for?
  • How will the new EC Merger Guidelines impact the assessment?
  • What do FDI screening rules mean for your deal in practice and how do you navigate them when multiple jurisdictions are involved?
  • Where is the regulatory environment for M&A headed, and what do the latest developments mean for deals in the pipeline?
With the regulatory framework governing M&A growing increasingly complex, this webinar will equip you with a clear understanding of the key regulatory checkpoints in a deal and the tools to navigate them with confidence.
Please contact Danica Schiefer with any questions

For more information, please visit these areas: Corporate — Brussels Practice, Antitrust and Competition — Brussels Practice, Regulatory — Brussels Practice

Participants

Insights

Webinar | 12.10.26

The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.

View All Insights